|
|
|
|
|
|
|
NervGen Pharma Announces Leadership Transition
|
Vancouver, BC, September 23, 2022--NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Board of Directors and Paul Brennan have mutually agreed that Mr. Brennan will step down as President & Chief Executive Officer and a member of the Board, effective immediately.
|
|
|
|
|
|
|
|